Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Concurrent pembrolizumab and chemotherapy in classical Hodgkin lymphoma

Ryan Lynch • 13 Dec 2021
ASH 2021
Hodgkin Lymphoma Lymphoma Antibodies Checkpoint inhibitors Dacarbazine Doxorubicin Pembrolizumab Vinblastine

Ryan Lynch, MD, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, discusses concurrent pembrolizumab, an anti-PD⁠-⁠1 monoclonal antibody, with AVD (doxorubicin, vinblastine, and dacarbazine) in patients with classical Hodgkin lymphoma (cHL). The treatment regimen displayed promising efficacy and safety and in patients. However, the interim-positron emission tomography (PET) scan results did not align with the high progression-free survival rates observed, and cell-free DNA (cfDNA) may predict outcomes more accurately. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Ryan Lynch

0:55
Mosunetuzumab in untreated FL and MZL: a response-adapted trial
Ryan Lynch • 8 Dec 2023
1:15
Polatuzumab vedotin combined with chemotherapy in untreated large B-cell lymphoma
Ryan Lynch • 8 Dec 2023
1:31
Pembrolizumab plus AVD in cHL: long-term follow-up of a Phase II study
Ryan Lynch • 8 Dec 2023
1:09
Update on parsaclisib in patients with R/R FL treated in the CITADEL-203 trial
Ryan Lynch • 8 Dec 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals